Search results for " Ulcerative"

showing 10 items of 158 documents

Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease

2019

Background Inflammatory bowel disease ( IBD ) is characterized by a low prevalence of traditional risk factors, an increased aortic pulse‐wave velocity ( aPWV ), and an excess of cardiovascular events. We have previously hypothesized that the cardiovascular risk excess reported in these patients could be explained by chronic inflammation. Here, we tested the hypothesis that chronic inflammation is responsible for the increased aPWV previously reported in IBD patients and that anti‐TNFa (anti‐tumor necrosis factor‐alpha) therapy reduce aPWV in these patients. Methods and Results This was a multicenter longitudinal study. We enrolled 334 patients: 82 patients with ulcerative colitis, 85 pati…

MaleLongitudinal studyTime FactorsSettore MED/09 - Medicina InternaAorta ThoracicBlood Pressure030204 cardiovascular system & hematologyGastroenterologyInflammatory bowel diseaseulcerative coliti0302 clinical medicineRisk Factorsarterial stiffneVascular DiseaseTumor necrosis factor-alphaEndoscopy Digestive SystemProspective Studies030212 general & internal medicinePulse wave velocityOriginal ResearchCrohn diseasetumor necrosis factor‐alphaUlcerative colitisC-Reactive Proteinarterial stiffnessCardiovascular DiseasesHypertensionFemaleTumor necrosis factor alphamedicine.symptomCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtypulse wave velocityInflammationPulse Wave Analysis03 medical and health sciencesVascular StiffnessInternal medicinemedicineHumansIn patientulcerative colitisbusiness.industryInflammatory Bowel Diseasesmedicine.diseasearterial stiffness; Crohn disease; inflammation; pulse wave velocity; tumor necrosis factor‐alpha; ulcerative colitis; Cardiology and Cardiovascular MedicineinflammationArterial stiffnessbusinessBiomarkersFollow-Up Studies
researchProduct

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

2015

Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab. Aims: To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model. Methods: A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this po…

MaleModels StatisticalDose-Response Relationship DrugUlcerativeColitisInfliximabTreatment OutcomeGastrointestinal AgentsHumanslcsh:Diseases of the digestive system. GastroenterologyColitis UlcerativeComputer SimulationFemalePharmacokineticslcsh:RC799-869Monte Carlo Method
researchProduct

Unusual B cell morphology in inflammatory bowel disease.

2012

B lymphocytes express various different types of surface immunoglobulins that are largely unrelated to other hematological lines, although some reports have described a relationship between malignant B cells and other cells such as macrophages. Multiple genes of hematopoietic lineage, including transcription factors, are co-expressed in hematopoietic stem cells and progenitors, a phenomenon referred to as "lineage priming". Changes in the expression levels and timing of transcription factors can induce the lineage conversion of committed cells, which indicates that the regulation of transcription factors might be particularly critical for maintaining hierarchical hematopoietic development. …

MalePathologyCD79BiopsyUlcerativeSmallInflammatory bowel diseaseInflammatory bowel diseaseMucosal immunityCrohn DiseaseIntestine SmallLymphocytesMicroscopyB-Lymphocytesmedicine.diagnostic_testMiddle AgedColitisFucosyltransferasesIntestineSurfaceHaematopoiesismedicine.anatomical_structureAntigens SurfaceFemaleStem cellB-1 B cellsAdultmedicine.medical_specialtyLymphocyte homingColonLewis X AntigenBiologyFluorescencePathology and Forensic MedicineAntigeninflammatory bowel diseaseBiopsymedicineHumansCell LineageProgenitor cellAntigensB cellInflammatory bowel disease; Inflammation; Mucosal immunity; Lymphocytes; B-1 B cells; Lymphocyte homing; CD15+cells; Adult; Antigens Surface; B-Lymphocytes; Biomarkers; Biopsy; Cell Lineage; Cell Nucleus; Colitis Ulcerative; Colon; Crohn Disease; Female; Fucosyltransferases; Humans; Immunoglobulin M; Inflammatory Bowel Diseases; Intestine Small; Lewis X Antigen; Male; Microscopy Fluorescence; Middle Aged; RectumInflammationCell NucleusRectumCell Biologymedicine.diseaseInflammatory Bowel DiseasesImmunoglobulin MMicroscopy FluorescenceImmunologyColitis UlcerativeCD15+cellsBiomarkersPathology, research and practice
researchProduct

Pulse wave velocity differs between ulcerative colitis and chronic kidney disease

2017

Background: We hypothesized that a reversal of the physiological stiffness gradient, previously reported in end-stage renal disease, begins in the early stages of chronic kidney disease (CKD) and that chronic inflammation produces a different arterial phenotype in patients with ulcerative colitis (UC). Objectives: To assess the extent of arterial stiffening in the central (carotid-femoral pulse wave velocity, cf.-PWV) and peripheral arteries (carotid-radial pulse wave velocity, cr-PWV) and to explore the determinants of the stiffness gradient in UC and in CKD. Methods: We enrolled 45 patients with UC, 45 patients with stage 3-4 CKD and 45 matched controls. Results: Despite the comparable cf…

MalePathologyDisease030204 cardiovascular system & hematologyurologic and male genital diseases0302 clinical medicine030212 general & internal medicineStage (cooking)ChildPulse wave velocityAged 80 and overArterial stiffness; Chronic renal failure; Inflammation; Pulse wave velocity; Stiffness mismatch; Ulcerative colitis; Internal MedicineMiddle AgedUlcerative colitisArterial stiffnessPeripheralArterial stiffnecardiovascular systemCardiologyFemalemedicine.symptomGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentInflammationPulse Wave Analysis03 medical and health sciencesYoung AdultVascular StiffnessInternal medicinemedicineChronic renal failureInternal MedicineHumansRenal Insufficiency ChronicAgedInflammationUlcerative colitibusiness.industrymedicine.diseasePulse wave velocityCross-Sectional StudiesUlcerative colitisCase-Control StudiesMultivariate AnalysisArterial stiffnessLinear ModelsColitis UlcerativeStiffness mismatchbusinessKidney disease
researchProduct

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

2016

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…

MaleSettore MED/07 - Microbiologia E Microbiologia Clinicaved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologyInflammatory bowel diseaselaw.inventionProbioticchemistry.chemical_compound0302 clinical medicineLactobacillus acidophiluslawMesalamineBifidobacteriumSettore MED/12 - GastroenterologiabiologyLactobacillus salivariusMicrobiotaMedicine (all)Anti-Inflammatory Agents Non-Steroidalfood and beveragesMiddle AgedUlcerative colitisLactobacillus acidophilusTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleBifidobacteria; Inflammatory bowel diseases; Lactobacilli; Microbiota; Ulcerative colitis; Medicine (all); Biochemistry Genetics and Molecular Biology (all)Adultmedicine.medical_specialtyCombination therapyinflammatory bowel diseasesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMesalazineDouble-Blind MethodBifidobacteriaInternal medicinemedicineHumansulcerative colitisAgedAnalysis of VarianceBifidobacterium bifidumUlcerative colitiBiochemistry Genetics and Molecular Biology (all)ved/biologybusiness.industryProbioticslcsh:Rbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia GeneralechemistryLactobacilliLigilactobacillus salivariusColitis UlcerativeBifidobacterium bifidumbusiness
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Subcutaneous emphysema, pneumomediastinum and pneumoperitoneum after diagnostic colonoscopy for ulcerative colitis: a rare but possible complication …

2010

Dear Editor: Colonoscopy is regarded as a safe procedure, but complications may occur. The most dreaded are perforation and massive bleeding of the colon. The incidence of perforation is low but, despite increased experience with the procedure, it remains unchanged over time and in a large population study ranges from 0.6 to 1 per 1.000 procedures, depending on the centre and the data source. Few studies have assessed risk factors for colonoscopy-related bleeding and perforation. Gatto et al. have reported that there was a significant trend in the incidence of perforation with increasing age, people aged 75 years or older having a fourfold risk as compared to those aged 65–69 years; same re…

Malemedicine.medical_specialtyAbdominal painmedicine.medical_treatmentPerforation (oil well)ColonoscopyPneumoperitoneumPneumoperitoneumLaparotomymedicinePneumomediastinumMediastinal EmphysemaAged 80 and overmedicine.diagnostic_testbusiness.industryRisk FactorGeneral surgeryGastroenterologyColonoscopymedicine.diseaseUlcerative colitisSubcutaneous EmphysemaSurgerySettore MED/18 - Chirurgia GeneraleColitis UlcerativeLaparoscopyAged 80 and over; Colitis Ulcerative; Colonoscopy; Humans; Laparoscopy; Male; Mediastinal Emphysema; Pneumoperitoneum; Risk Factors; Subcutaneous Emphysema; Gastroenterologymedicine.symptombusinessSubcutaneous emphysemaHumanInternational Journal of Colorectal Disease
researchProduct

Bone status assessed by quantitative ultrasound in children with inflammatory bowel disease: a comparison with DXA

2016

Background: To determine the bone status in children with inflammatory bowel diseases (IBD) using quantitative ultrasound (QUS) measurement at hand phalanges and compare the obtained results with dual-energy X-ray absorptiometry (DXA). Methods: Fifty-one children with IBD underwent DXA and QUS measurements at hand phalanges in the year 2013. The control group for the QUS consisted of 460 children. Reference data for DXA comes from Hologic Explorer. Results: QUS measurements did not differ significantly between IBD patients and healthy controls. There was no difference between UC and CD subjects. DXA measurements in patients with IBD were lower than in the healthy population. Tanner stage an…

Malemedicine.medical_specialtyAdolescentNutritional Status030209 endocrinology & metabolismInflammatory bowel diseasesInflammatory bowel diseaseFinger Phalanges03 medical and health sciencesquantitative ultrasoundAbsorptiometry Photon0302 clinical medicineCrohn DiseaseAdrenal Cortex HormonesBone DensityPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansIn patientStage (cooking)Childbone mineral statusUltrasonographyBone mineralHepatologybusiness.industryHealthy populationAge FactorsGastroenterologyInflammatory Bowel DiseasesNutritional statusmedicine.diseasedigestive system diseasesQuantitative ultrasoundBone Diseases MetabolicNutrition AssessmentCase-Control StudiesColitis UlcerativeFemale030211 gastroenterology & hepatologyRadiologybusinessExpert Review of Gastroenterology & Hepatology
researchProduct

Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation.

2006

Immunosuppression is currently the treatment of choice for severe inflammatory bowel disease (IBD). Thus, it was anticipated that the course of preexisting IBD should improve after orthotopic liver transplantation (OLT). Despite sufficient allograft immunosuppressive therapy, however, exacerbation of IBD or the development of de novo IBD after OLT were described in some cases, primarily in patients transplanted for end-stage primary sclerosing cholangitis (PSC). In addition, the development of de novo IBD in patients undergoing OLT for indications other than PSC was described. Evaluating our collective of 314 liver transplanted patients we found five patients transplanted for various indica…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentBiopsyAutoimmune hepatitisLiver transplantationGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicinemedicineHumansImmunosuppression TherapyHepatologybusiness.industryGastroenterologyImmunosuppressionHepatitis BMiddle Agedmedicine.diseaseUlcerative colitisdigestive system diseasesTacrolimusLiver Transplantationsurgical procedures operativeColitis UlcerativeFemalebusinessThe American journal of gastroenterology
researchProduct